HC Wainwright Lifts Earnings Estimates for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for Gain Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.95) for the year, up from their previous forecast of ($1.06). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

A number of other analysts have also recently weighed in on the stock. Oppenheimer restated an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday, August 9th.

Gain Therapeutics Trading Up 0.6 %

Gain Therapeutics stock opened at $1.74 on Wednesday. The firm has a 50 day simple moving average of $2.08 and a 200-day simple moving average of $1.71. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The stock has a market capitalization of $46.14 million, a PE ratio of -1.58 and a beta of 0.33. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $5.33.

Institutional Trading of Gain Therapeutics

A number of large investors have recently added to or reduced their stakes in GANX. Hohimer Wealth Management LLC bought a new stake in Gain Therapeutics during the second quarter worth approximately $422,000. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics in the 2nd quarter valued at approximately $66,000. Renaissance Technologies LLC lifted its position in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after acquiring an additional 72,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.